What is the TAPUR Study?
The Targeted Agent and Profiling Utilization Registry (TAPURTM) Study offers a clinical trial opportunity for patients with advanced cancer who have not responded or are no longer responding to standard treatment and who have genomic alterations in their tumors that can be targeted with a TAPUR Study drug.
Who is Eligible?
Review the statements below to find out if you may be eligible for the TAPUR Study. If you can answer “yes” to all of the statements below, you may qualify for the TAPUR Study. The American Society of Clinical Oncology (ASCO), the TAPUR Study sponsor, recommends discussing the TAPUR Study with your doctor, or for more information, contact the TAPUR Study team using the “Contact Us” form below.
* Some restrictions apply. Not all TAPUR Study therapies are available for participants under 18 years of age. Contact a participating TAPUR Study clinical site or the TAPUR Study team using the “Contact Us” form below to learn about the eligibility age for a specific study drug.
**Subject to cohort availability. As of June 2018, enrollment of patients with multiple myeloma and non-Hodgkin lymphoma is suspended until further notice.
How the TAPUR Study Works
Participating TAPUR Study Clinical Sites
Most of the clinical site locations participating in the TAPUR Study are a part of a larger network, and all questions and/or referrals should be directed to the primary contact at the main operations center.
Latest News & Updates on the Study
View the TAPUR Study updates, including the latest study news and ongoing analyses.
The ASCO TAPUR Study team recognizes that cancer research advocates are important stakeholders and partners in clinical trials and can contribute to the planning and conduct of the TAPUR Study, as well as assist in increasing public and patient awareness. We welcome advocates to complete our brief online survey and sign up to receive communications and updates about the TAPUR Study and, for those interested, information on how to get involved.